Evolus, Inc. (EOLS), a performance beauty company, has unveiled its new campaign "Drop the F Word" to challenge outdated perceptions of aesthetic injectables ahead of the commercial launch of Evolysse.
This new line of hyaluronic acid - HA gels is designed to treat moderate to severe facial wrinkles while delivering natural-looking, long-lasting results.
The campaign addresses rising consumer "filler fatigue," as many now associate the word "filler" with artificial or overdone results. Based on extensive consumer research, Evolus is removing the term "filler" from its language, introducing Evolysse as a modern solution that reflects evolving beauty standards.
CEO David Moatazedi emphasized the need to move beyond the term "filler" and focus on personalized, authentic beauty results. Backed by Cold-X technology, Evolysse is the first major HA innovation in over a decade and is designed to preserve the HA molecule's natural structure for more refined outcomes.
Evolus is using this launch to encourage the industry to reframe how aesthetic treatments are discussed, aiming to foster a more informed and confidence-driven beauty experience.
EOLS is currently trading at $10.38 or 1.47% higher on the Nasdaq Global Market.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.